IDIBAPS – Hospital Clínic investigators lead a consensus statement on Plasma cell leukemia

Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. A consensus statement about this disease, to be published in Leukemia, focuses on diagnostic requirements, response criteria, and treatment recommendations. Dr Carlos Fernández de Larrea, a postdoc investigator at the IDIBAPS team Hematological oncology and the Department of Hematology of the Hospital Clínic de Barcelona, is the first author of this document by the international myeloma working group (IMWG). Dr. Joan Bladé, another IDIBAPS – Hospital Clínic specialist, is also among the authors.

Primary PCL is a distinct clinic-pathologic entity with different cytogenetic and molecular findings. The clinical course is aggressive with short remissions and survival duration. The diagnosis is based upon the percentage and absolute number of plasma cells in the peripheral blood. The new document proposes that the thresholds for diagnosis be reexamined and consensus recommendations are made for diagnosis and treatment, as well as, response and progression criteria.

The IDIBAPS team Hematological oncology, led by Dr. Francisco Cervantes, is an international reference in the field of hematological oncology. Their work covers clinical, applied and basic research. With 41 Original articles published in 2011, and an average IF of 8.7 points per article, it is one of the most productive research teams at IDIBAPS.